# Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

> **NCT02951637** · PHASE2 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Lung Adenocarcinoma

## Interventions

- **DRUG:** Pemetrexed plus carboplatin combined with gefitinib
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT02951637
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2018-04
- **Final completion:** 2019-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2016-11-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951637, "Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02951637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*